WaveMan
WaveMan · Company
INVA · Innoviva, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

INVA Innoviva (INVA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001080014
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
182
13F, latest reported quarter

What the filings say about INVA

Congress, 1 year
No trades
Last one: sale, 2025-03-25

Innoviva insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Innoviva, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
DENNER ALEXANDER J
SELL
2025-03-06 SEC
1,196,746
$21.0M
+19.3%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (6 buys, 2 sales), the last on Mar 5, 2025.
  • +1.1% median (+0.8% mean) 90-day return after 6 previous buys.
  • The trade is 21.1% of the 5,658,705 shares held after it.
  • No other insider sold within 30 days.
  • 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DENNER ALEXANDER J sold about $21.0M of INVA on Mar 6, 2025, the largest insider sale at the company on our record; 182 funds added in the latest 13F quarter.
DENNER ALEXANDER J
SELL
2025-03-06 SECtraded 2025-03-05
270,374
$4.8M
+19.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (6 buys, 1 sale), the last on Mar 4, 2025.
  • +1.1% median (+0.8% mean) 90-day return after 6 previous buys.
  • The trade is 3.9% of the 6,855,451 shares held after it.
  • No other insider sold within 30 days.
  • 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DENNER ALEXANDER J sold about $4.8M of INVA on Mar 5, 2025, the largest insider sale at the company on our record; 182 funds added in the latest 13F quarter.
DENNER ALEXANDER J
SELL
2025-03-06 SECtraded 2025-03-04
151,175
$2.7M
+19.3%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 6, 2023.
  • +1.1% median (+0.8% mean) 90-day return after 6 previous buys.
  • The trade is 2.1% of the 7,125,825 shares held after it.
  • No other insider sold within 30 days.
  • 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DENNER ALEXANDER J sold about $2.7M of INVA on Mar 4, 2025, the largest insider sale at the company on our record; 182 funds added in the latest 13F quarter.
Zhen Marianne
Chief Accounting Officer
SELL
2023-11-17 SECtraded 2023-11-15
5,589
$78.3K
+54.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 20, 2021.
  • The trade is 12.3% of the 45,563 shares held after it.
  • No other insider sold within 30 days.
  • 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Zhen Marianne sold about $78.3K of INVA on Nov 15, 2023, the largest insider sale at the company on our record; 182 funds added in the latest 13F quarter.
Zhen Marianne
Chief Accounting Officer
SELL
2023-11-17 SECtraded 2023-11-15
5,405
$75.5K
+54.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 20, 2021.
  • The trade is 13.5% of the 40,158 shares held after it.
  • No other insider sold within 30 days.
  • 182 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Zhen Marianne sold about $75.5K of INVA on Nov 15, 2023, the largest insider sale at the company on our record; 182 funds added in the latest 13F quarter.
20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 15 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
182 funds bought in last quarter
more than 87% of Pharma & Biotech
Revenue
+14.7% year over year
more than 63% of Pharma & Biotech
Margin
65.9% net margin
more than 96% of Pharma & Biotech
Buybacks
$51.3M repurchased, FY to 2026-06-30
more than 58% of Pharma & Biotech
Short interest
10.1% of the float short (float per yahoo 2026-10-26) · 5.7 days to cover · settled 2026-09-30
more than 69% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch INVA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+15.3%12M
-4%+8%+21%+33%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns INVA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
11,555,209 sh
$262.4M
DIMENSIONAL FUND ADVISORS LP
4,494,053 sh
$102.1M
VANGUARD PORTFOLIO MANAGEMENT LLC
4,220,273 sh
$95.8M
RENAISSANCE TECHNOLOGIES LLC
4,036,532 sh
$91.7M
STATE STREET CORP
3,268,004 sh
$74.2M

Congress trades in INVA

STOCK Act disclosures, US House only, filed up to 45 days after the trade
George Whitesides
Sold 2025-03-25 · disclosed 29 days later
$250,001 - $500,000
George Whitesides
Sold 2025-03-24 · disclosed 30 days later
$50,001 - $100,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

INVA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

INVA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Pharmaceuticals ETF
$11.4M position · as of 2026-07-31
2.4%
WPG Partners Select Small Cap Value Fund
$5.6M position · as of 2026-05-31
2.4%
ETC 6 Meridian Small Cap Equity ETF
$2.7M position · as of 2026-05-31
2.1%
RIVER OAK DISCOVERY FUND
$373.0K position · as of 2026-07-31
2.0%
JAMES MICRO CAP FUND
$555.6K position · as of 2026-06-30
1.7%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.5M position · as of 2026-06-30
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 182 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

INVA financials

Revenue growth
+14.7%
XBRL, annual
Net margin
65.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$440.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+81.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$189.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.21x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Cash flow to debt
0.74x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Return on equity
+36.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+23.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+18.5%
operating income after a 14.8% effective tax rate, over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+11.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
5.12x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$1.2B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
FCF yield
+12.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
0.00x
P/E over trailing EPS growth of 1042%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$411.3M$358.7M$310.5M$331.3M
Gross profit$307.7M$296.2M$246.0Mn/a
Operating income$163.7M$166.9M$113.9Mn/a
Net income$271.2M$23.4M$179.7M$220.3M
EPS (diluted)3.300.362.202.37
Operating cash flow$196.9M$188.7M$141.1M$201.7M
Cash$550.9M$305.0M$193.5M$291.0M
Long-term debt$257.7M$256.3M$446.2M$444.2M
Buybacks$4.5M$14.8M$75.7M$8.5M
SEC XBRL, fiscal years, as known on 2026-10-28

INVA Stock Sonar score 5/7 axes

Find similar shapesCompare

INVA ranks highest on institutional and government (87th percentile) and profitability (82nd), and lowest on growth (63rd), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
82
Inputs
  • Return on equity+36.7% · 92 pct, sector of 545
  • Return on assets+23.5% · 93 pct, sector of 691
  • Return on invested capital+18.5% · 52 pct, sector of 45
  • Return on capital employed+11.9% · 91 pct, sector of 576
Financial health
68
Inputs
  • Debt to equity0.21x · 44 pct, sector of 352
  • Cash flow to debt0.74x · 91 pct, sector of 371
Growth
63
Inputs
  • Revenue growth, YoY+14.7% · 63 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
87
Inputs
  • Funds adding, latest quarter182 · 87 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
64
Inputs
  • Short interest, % of float+10.1% · 39 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+3.6% · 89 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

INVA filings, in plain words

Have members of Congress traded INVA?

Yes, but not in the year to 2026-10-28; the latest on record is a sale by George Whitesides dated 2025-03-25.

Read the full summary

Members of Congress have disclosed trades in INVA, none in the last year; the latest on record is a sale by George Whitesides dated 2025-03-25. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies